Regulation and Science: Biosimilars Waiting to Debut in the US
Regulation and Science: Biosimilars Waiting to Debut in the US Editorial by Josh Sternberg, Editor-in-Chief at Northeastern Univeristy Political Review The pharmaceutical industry is experiencing tectonic shifts, with widespread effects on the traditional business models of pharmaceutical companies. Drying pipelines, pricing pressures, health care reform, and rising costs of research and development are forcing pharmaceutical companies […]
Regulation and Science: Biosimilars Waiting to Debut in the US Read More »